secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001193125-24-080630
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca raises $45M in oversubscribed private placement at $2.06/share
---------------------------------------------------------------------

- Sold 21,844,660 shares at $2.06 each to institutional investors; gross proceeds ~$45M.
- Private placement led by new and existing healthcare investors; BofA Securities acted as placement agent.
- Expected closing on or about April 2, 2024, subject to customary closing conditions.
- Proceeds to fund R&D, working capital; combined cash expected to fund operations into H2 2026.
- Press release highlights naporafenib plus trametinib data showing 13-14 months median OS in NRAS-mutant melanoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312524080630/0001193125-24-080630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312524080630/d808774d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-080630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer